Intensity Therapeutics Inc 2026年季度报告

FORM 10-Q_________________________ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934For the quarterly period ended June 30, 2026ORTRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934For the transition period from __________ to __________Commission file number 001-41109_________________________ INTENSITY THERAPEUTICS, INC. (Exact name of registrant as specified in its charter)_________________________ 1 Enterprise Drive, Suite 430, Shelton, CT(Address of Principal Executive Offices) (203) 221-7381 Registrant’s telephone number, including area code Securities registered pursuant to Section 12(b) of the Act: Name of Each Exchange on WhichRegistered Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the SecuritiesExchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports),and (2) has been subject to such filing requirements for the past 90 days. YesNo Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submittedpursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that theregistrant was required to submit such files). YesNo Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smallerreporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smallerreporting company,” and "emerging growth company" in Rule 12b-2 of the Exchange Act. Accelerated filerSmaller reporting companyEmerging growth company If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period forcomplying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act). YesNo As of August7, 2026, the registrant had 3,264,879 shares of common stock outstanding. CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING STATEMENTS This Quarterly Report on Form 10-Q contains forward-looking statements that involve substantial risks and uncertainties. Allstatements, other than statements of historical facts, contained in this report, including statements regarding our strategy, futureoperations, future financial position, future revenue, projected costs, prospects, plans, and objectives of management and expectedmarket growth are forward-looking statements. These statements involve known and unknown risks, uncertainties and other importantfactors that may cause our actual results, performance or achievements to be materially different from any future results, performanceor achievements expressed or implied by the forward-looking statements. The words “anticipate,” “believe,” “estimate,” “expect,” “intend,” “may,” “plan,” “predict,” “will,” “project,” “would” and similarexpressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifyingwords. These forward-looking statements include, among other things, statements about: • the initiation, timing, progress and results of future preclinical studies and clinical trials, and our research and developmentprograms; • our need to raise additional funding to complete our clinical trials and before we can expect to generate any revenues from productsales;• our plans to develop and commercialize our product candidates;• the timing or likelihood of regulatory filings and approvals;• the ability of our research to generate and advance additional product candidates;• the implementation of our business model, strategic plans for our business, product candidates and technology;• our commercialization, marketing and manufacturing capabilities and strategy;• the rate and degree of market acceptance and clinical utility of our system;• our competitive position;• our intellectual property position;• developments and projections relating to our competitors and our industry;• our ability to maintain and establish collaborations or obtain additional funding;• our expectations related to the use of our cash and cash equivalents and investments;• our estimates regarding expenses, future revenue, capital requirements and needs for additional financing;• our ability to remain listed on The Nasdaq Capital Market; and• other factors discussed herein and under the heading “Risk Factors” in our Annual Report on Form 10-K filed with the U.S.Securities and Exchange Commission (the “SEC”) on March 27, 2026 (the “2025 Annual Report”), and this Quarterly Report onForm 10-Q. In light of these assumptions, risks and uncertainties, the results and events discusse